Potential strategies for inflammatory mediator manipulation: Retrospect and prospect

World Journal of Surgery

Volumn 20, Issue 4, 1996, Pages 447-453

  Fisher Jr , Charles J ^a   Zheng, Yunli ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ ANTAGONIST; CENTOXIN; EDOBACOMAB; ENDOTOXIN; ENDOTOXIN ANTIBODY; IBUPROFEN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; POLYCLONAL ANTIBODY; PROSTAGLANDIN SYNTHASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE SEPSIS; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INTENSIVE CARE UNIT; MEDIATOR RELEASE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SEPSIS; SEPTIC SHOCK;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; ENDOTOXINS; FORECASTING; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; MULTIPLE ORGAN FAILURE; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029986796     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689900070     Document Type: Review

References (89)

1. Wenzel, R.P.: The mortality of hospital-acquired blood stream infections: need for a new vital statistic? Int. J. Epidemiol. 17:225, 1988
2. Bone, R.C., Fisher, C.J., Jr., Clemmer, T.P., et al.: Sepsis syndrome: a valid clinical entity. Crit. Care Med. 17:389, 1989
3. Centers for Disease Control: Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. M.M W.R. 39:31, 1990
4. Greenman, R.L., Schein, R.M.H., Martin, M.A, et al.: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. J.A.M A. 266:1097, 1991
5. Ziegler, E.J., Fisher, C.J., Jr., Sprung, C.L., et al.: Treatment of gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324:429, 1991
6. Fisher, C.J., Jr., Bellingan, G.: Immunotherapy of sepsis syndrome: a comparison of the available treatments. Klin. Wochenschr. 69(Suppl 26):162, 1991
7. Parillo, J.E., Parker, M.M., Natanson, C., et al.: Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113:227, 1990
8. Bone, R.C.: Pathogenesis of sepsis. Ann. Intern. Med. 115:457, 1991
9. Parillo, J.E.: Pathogenic mechanisms of septic shock. N. Engl. J. Med. 328:1471, 1993
10. Hesse, D.G., Tracey, K.J., Fong, Y , et al.: Cytokine appearance of human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet. 166:147, 1988
11. Tracey, K.J., Vlassara, H., Cerami, A.: Cachectin/tumor necrosis factor. Lancet 1:1122, 1989
12. Waage, A., Brandtzag, P., Halstensen, A., et al.: The complex pattern of cytokines in serum from patients with meningococcal septic shock: association between interleukin-6, interleukin-1 and the fatal outcome. J. Exp. Med. 169:333, 1989
13. Marks, J.D., Marks, C.B., Luce, J.M., et al.: Plasma tumor necrosis factor in patients with septic shock. Am. J. Respir. Dis. 141:94, 1990
14. Cannon, J.G., Tompkins, R.G., Gelfand, J.A., et al.: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161:79, 1990
15. Calandra, T., Baumgartner, J.D , Gram, E.G , et al.: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha and interferon-gamma in the serum of patients with septic shock. J. Infect. Dis. 161:982, 1990
16. Fisher, C.J., Jr , Opal, S.M., Dhainaut, J.F., et al.: Anti-TNF IgG monoclonal antibody (CB0006) in sepsis syndrome: pharmacokinetics, safety and role of pretreatment IL-6 as a predictor of time of survival. Circ. Shock 34:167, 1991
17. Van Zee, K.J., De Forge, L.E., Fischer, E., et al.: IL-8 in septic shock, endotoxemia and after IL-1 administration. J. Immunol. 146:3418, 1991
18. Van Zee, K.J., Fischer, E., Hawes, A.S., et al.: Effects of intravenous IL-8 administration in nonhuman primates. J. Immunol. 148:1746, 1992
19. Michie, H.R., Monogue, K.R., Spriggs, D.R., et al.. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481, 1988
20. Fischer, E., Marano, M.A , VanZee, K.J., et al: Interleukin-1 receptor blockade improves survival and hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest. 89:1551, 1992
21. Wakabayashi, G., Gelfand, J.A., Burke, J.F., et al.: A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 5:338, 1991
22. Aiura, K., Gelfand, J.A., Burke, J.F., et al.: Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1beta in rabbits. Infect. Immun. 61:3342, 1993
23. Granowitz, E.V., Santos, A A., Poutsiaica, D.D., et al.: Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet 338:1423, 1991
24. Strieter, R.M., Kunkel, S.L., Bone, R.C.: Role of tumor necrosis factor-alpha in disease states and inflammation. Crit. Care Med. 27:s447, 1993
25. Beutler, B., Grau, G E.: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit. Care Med. 21:s423, 1993
26. Tracey, K.J., Beutler, B., Lowry, S.F., et al.: Shock and tissue injury induced by recombinant human cachectin. Science 234:470, 1986
27. Okusawa, S., Gefand, J.A., Ikejima, T., et al.: Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin Invest. 81:1162, 1988
28. Ziegler, E.J., McCutchan, J.A., Fierer, J., et al.: Treatment of gram negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1225, 1982
29. Baumgartner, J-D., Glauser, M.P., McCutchan, J.A., et al.: Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59, 1985
30. Schedel, I., Driekhausen, U., Nentwig, B., et al.: Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit. Care Med. 19:1104, 1991
31. Exley, A.R., Cohen, J., Buurman, W., et al.: Murine monoclonal antibody to recombinant human tumor necrosis factor in the treatment of severe septic shock. Lancet 335:1275, 1990
32. Fisher, C.J., Jr., Opal, S.M., Dhainaut, J.F., et al.: Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. 21:318, 1993
33. Fisher, C.J., Jr., Slotman, G.J., Opal, S.M., et al.: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome - a randomized, open-label, placebo-controlled trial. Crit. Care Med. 22:12, 1994
34. Fisher, C J., Dhainaut, J.F., Opal, S.M., et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. J.A.M A. 271:1836, 1994
35. Abraham, E., Wunderink, R., Silverman, H., et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. J.A.M.A. 273:934, 1995
36. Bone, R.C., Fisher, C.J., Jr., Clemmer, T.P., et al.: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317:653, 1987
37. Hinshaw, L., Sprung, C.L., Peducci, P., et al.: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N. Engl. J. Med. 317:659, 1987
38. Giroir, B.P.: Mediators of septic shock: new approaches for interrupt-ing the endogenous inflammatory cascade. Crit. Care Med. 21:780, 1993
39. Morrison, D.C., Ryan, J.L.: Bacterial endotoxins and host immune responses. Adv. Immunol. 28:293, 1979
40. Morrison, D.C., Ulevitch, R.J.: The effects of bacterial endotoxins on host mediation systems. Am. J. Pathol. 93:526, 1978
41. Hoffmann, W.D., Natanson, C.: Endotoxin in septic shock. Anesth. Analg. 77:613, 1993
42. Mathison, J.C., Wolfson, E., Ulevitch, R.J.: Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Invest. 81:1925, 1988
43. Okusawa, S., Gefand, J.A., Ikejima, T., et al.: Interleukin-1 induces a shock-like state in rabbits, synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81:1162, 1988
44. Opal, S.M., Cross, A.S., Kelly, N.M., et al.: Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J. Infect. Dis. 161:1148, 1990
45. Cannon, J.G., Tompkins, R.G., Gelfand, J.A., et al.: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect. Dis. 161:79, 1990
46. McCloskey, R.V., Straube, R.C., Sanders, C., et al.: Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 121:1, 1994
47. Weiss, J., Elsbach, P., Olsson, I., Odeberg, H.: Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J. Biol. Chem. 253:2664, 1978
48. Fisher, C.J., Jr., Opal, S.M., Marra, M.N., et al.: Bactericidal/permeability-increasing protein (BPI) reduces mortality in experimental sepsis. Circ. Shock 34:20, 1991
49. Fisher, C.J., Opal, S.M., Marra, M.N.: Bactericidal permeability increasing protein: a potent naturally occurring anti-endotoxin protein. In Mediators of Sepsis, M. Lamy, L.G. Thijs, editors. Heidelberg, Springer-Verlag, 1992
50. Marra, M.N., Thornton, M.B., Snable, J.L., Wilde, C.G., Scott, R.W.: Endotoxin-binding and neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit. Care Med. 22:559, 1994
51. Fisher, C.J., Marra, M.N., Palardy, B.A., et al.: Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study. Crit. Care Med. 22:553, 1994
52. Opal, S.M., Palardy, J.E., Marra, M.N., et al.: Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet 344:429, 1994
53. Beutler, B., Cerami, A.. Cachectin. more than a tumor necrosis factor. N. Engl. J. Med. 316:379, 1987
54. Marks, J.D., Marks, C.B., Luce, J.M., et al.: Plasma tumor necrosis factor in patients with septic shock. Am. J. Respir. Dis. 141:94, 1990
55. Hesse, D.G., Tracey, K.J., Fong, Y., et al.: Cytokine appearance of human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet. 166:147, 1988
56. Waage, A., Halstensen, A., Spevik, T.: Association between tumor necrosis factor in serum and total outcome in patients with meningococcal disease. Lancet 1:355, 1987
57. Tracey, K., Fong, Y., Hesse, D.G., et al.: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662, 1987
58. Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D., Wallach, D.: A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264:11974, 1989
59. Olsson, I., Lantz, M., Nilsson, E , et al.: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur. J. Haematol. 42:270, 1989
60. Robaye, B., Hepburn, A., Lecocq, R., Fiers, W., Boeynaems, J.M., Dumont, J.E.: Tumor necrosis factor-alpha induces the phosphorylation of 28 kDa stress proteins in endothelial cells: possible role in protection against cytotoxiciyy? Biochem. Biophys. Res. Commun. 163:301, 1989
61. Schutze, S., Scheurich, P., Pfizenmaier, K., Kronke, M.: Tumor necrosis factor signal transduction: tissue-specific serine phosphorylation of a 26-kDa systolic protein. J. Biol. Chem. 264:3562, 1989
62. Vilcek, J., Lee, T.H.: Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J. Biol. Chem. 266:7313, 1991
63. Dinarello, C.A.: Interleukin-1 and its biologically related cytokines. Adv. Immunol. 44:153, 1989
64. Damas, P., Reuter, A., Gysen, P., et al.: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit. Care Med. 17:975, 1989
65. Waage, A., Brandtzag, P., Halstensen, A., et al.: The complex pattern of cytokines in serum from patients with meningococcal septic shock: association between interleukin-6, interleukin-1 and the fatal outcome. J. Exp. Med. 169:333, 1989
66. Eisenberg, S.P., Evans, R.J., Arend, W.P., et al.: Primary structure and functional expression from complimentary DNA of a human interleukin-1 receptor antagonist. Nature 343:341, 1990
67. Hannum, C.H., Wilcox, C.J., Arend, W.P., et al.: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336, 1990
68. Arend, W.P., Welgus, H.G., Thompson, R.C., Eisenberg, S.P.: Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J. Clin. Invest. 85:1694, 1990
69. Ohlsson, K., Bjork, P., Bergenfeldt, M., et al.: An interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550, 1990
70. Fischer, E., Marano, M.A., Barber, A., et al.: A comparison between the effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am. J. Physiol. 261:R442, 1991
71. Braquet, P., Paubert-Braquet, M., Bourgain, R.H., Bussolinl, F., Hosford, D.: PAR/cytokines autoregulated feedback networks in microvascular injury: consequences in shock, ischemia and graft rejection. J. Lipid Med. 1:75, 1989
72. Sanchez-Crespo, M., Fernandez-Gallardo, S.: Pharmacological modulation of PAF: a therapeutic approach to endotoxin shock. J. Lipid Med. 4:127, 1991
73. Dhainaut, J.F., Tenaillon, A., Le Tulzo, Y., et al., Platelet-activating factor receptor antagonist BN52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit. Care Med. 22:1720, 1994
74. Feuerstein, G., Hallenbeck, J.M.: Prostaglandins, leukotrienes and platelet activating factor in shock. Annu. Rev. Pharmacol. Toxicol. 27:301, 1987
75. Chang, S.W., Feddersen, C.O., Henson, P.M., Voelkel, N.F.: Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J. Clin. Invest. 79:1498, 1987
76. Diez, F.L., Nieto, M., Fernandez-Gallardo, S., Gijoin, M.A., Sanchez-Crespo, M.: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia J. Clin. Invest. 83:1733, 1989
77. Bussolino, F., Porcellini, M.G., Varese, L., Bosia, A.: Intravascular release of platelet activating factor in children in sepsis. Thromb Res. 48:619, 1987
78. Cortech News Release: Phase II Bradycor Trial Does Not Show Clinically Meaningful Reduction of 28-Day Mortality in Sepsis. Denver, Cortech, 1994
79. Schumer, W.: Steroids in the treatment of clinical septic shock. Ann. Surg. 184:333, 1976
80. Calandra, T., Glauser, M.P., Schellekens, J., Verhoef, J.: Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect. Dis. 158:312, 1988
81. McCutchan, J.A., Wolf, J.L., Ziegler, E.J., Braude, A.I.: Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infection in patients with prolonged neutropenia. Schweiz. Med. Wochenschr. 113(Suppl.14): 40, 1983
82. Intravenous Immunoglobulin Collaborative Study Group: Prophylactic intravenous administration of standard immune globulin as compared with cor-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N. Engl. J. Med. 27:234, 1992
83. J5 Study Group: Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J. Infect. Dis. 165:695, 1992
84. Wenzel, R., Bone, R.C., Fein, A., et al.: Results of a second double-blind, randomized, controlled trial of anti-endotoxin antibody E5 in gram-negative sepsis [abstract]. In Program and Abstracts of the Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy, 1991, p. 294
85. Luce, J.M.: Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit. Care Med. 21:1233, 1993
86. Fisher, C.J., Jr , Agosti, J.M., Opal, S.M., et al.: Treatment of patients with septic shock with tumor necrosis factor receptor Fc fusion protein: a randomized, double-blind, placebo-controlled trial. (submitted)
87. 2 formation in human sepsis syndrome: effects of cyclooxygenase inhibition. Am. Rev. Respir. Dis. 114:1095, 1991
88. Bernard, G R., Carroll, F., Christman, W., et al.: Quality of life in survivors of sepsis syndrome: data from the ibuprofen in sepsis clinical tndence to: aerial. Am. Rev. Respir. Dis. 145:A217, 1992
89. Sprung, C.L., Caralis, P.V., Marcial, E.H., et al.: The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N. Engl. J. Med. 311:1137, 1984